News Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal Cancer drug developer Veraxa Biotech has reached a deal to merge with a SPAC in a deal that will give it a Nasdaq listing and a $1.6bn-plus valuation.
News Merida raises $121m for Graves drug, and other financings Our round-up of recent biotech financings includes rounds for Merida, Glycomine, Attovia, Imbria, and Solu Therapeutics.
News MoonLake secures $500m for lead drug, plus other financings MoonLake secures $500m in financing for lead inflammatory disease drug sonelokimab while AIRNA, Atsena, and Neurona complete $100m+ private rounds.
News Alphabet's Isomorphic raises $600m for AI drug discovery Isomorphic Labs has raised a whopping $600 million to refine its artificial intelligence-powered drug discovery engine and advance its pipeline.
News Character raises $93m for eye drugs, plus other financings Recent financings in the biotech space include rounds for Character Bio, Tempero, Epicrispr, Hillstar Bio, and Ampersand Biomedicines.
News Phase 3 readout puts Opthea at risk of insolvency After its lead wet AMD drug failed a phase 3 trial, Opthea may have to make massive repayments to investors that would threaten its viability.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face